Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06807762

Safety and Pharmacokinetics of Extrato de Cannabis Sativa GreenCare

The goal of this Phase I clinical trial is to assess the pharmacokinetic availability and safety and tolerability profile of Extrato de Cannabis sativa GreenCare 79.14 mg/mL. The main question it aims to answer is:

• Is the Extrato de Cannabis sativa GreenCare 79,14 mg/mL safe?

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

GreenCare Pharma

Vinhedo, São Paulo, 13288006, Brazil

Location status: Recruiting

Location contact

Fernando Pacheco, MD

PRINCIPAL_INVESTIGATOR

Study coordinator, MsC PhD

CONTACT

[email protected]

+55 11 942562895

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women from 18 to 65 years, inclusive;
  • Body weight ≥ 50 kg and BMI between 18.5 and 30 kg/m2, inclusive;
  • Be healthy according to medical history, i.e., have laboratory test results within normal ranges and/or any deviations from normal classified as clinically insignificant;
  • Be exclusively participating in this clinical study during the research period;
  • Understand and comply with the protocol requirements and consent to participate in the study by signing the Informed Consent Form (ICF) approved by an Ethics Committee (EC).

Exclusion criteria

Having participated in any experimental study or ingested any experimental drug within 1 (one) year prior to the start of this study;

  • Inability to use oral medication and/or cooperate with investigators due to cognitive impairment or mental state;
  • Reported allergy to any component of Cannabis sativa extract 79.14 mg/mL;
  • Personal or first-degree family history of schizophrenia, bipolar affective disorder, psychotic symptoms, suicidal ideation, planning and/or attempt, and/or severe uncontrolled psychiatric comorbidities, at the discretion of the principal investigator;
  • Donated blood within four (4) months prior to signing the Informed Consent Form (ICF);
  • Being pregnant, breastfeeding, intending to become pregnant during the study period, or having a positive result for urinary β-HCG testing;
  • Reported use of Cannabis and/or its derivatives for any purpose in the past 6 months;
  • Personal history of Cannabis use disorder and/or other illicit drug use disorder;
  • Personal history of alcohol, tobacco, opioid, benzodiazepine, barbiturate, and/or other substance use disorders, such as St. John's Wort;
  • Smokers or ex-smokers who quit less than 6 months ago;
  • Consumed alcoholic beverages within 24 hours before the study confinement period;
  • Any condition that prevents participation at the discretion of the investigator;
  • Dietary habits that prevent ingestion of the diet provided during the study;
  • Any clinical or laboratory finding or therapy that, at the investigator's discretion, may place the participant at risk or interfere with study objectives or outcomes;
  • Non-compliance with the complete ingestion of the diet provided - determination at the discretion of the responsible physician.

Treatment and study plan

Cannabis oil

Drug

Healthy subjects will be treated with a solution of Cannabis sativa extract diluted in MCT oil, at doses ranging from 39.62 mg to 791.4 mg. This protocol will be divided into two stages:

Stage 1 - Determination of the Maximum Tolerated Dose (MTD): Participants (n=60) will be dynamically randomized and will receive Cannabis sativa extract (GreenCare, 79.14 mg/mL) as a single dose after breakfast, with doses ranging from 39.62 mg to 791.4 mg.

Stage 2 - Assessment of the MTD: All participants (n=12) will receive the MTD determined in Stage 1, administered in two daily doses for 14 consecutive days.

Other names: Extrato de Cannabis sativa GreenCare 79.14 mg/mL

Primary outcomes

  1. Identification of the Maximum Tolerated Dose (MTD) of Cannabis sativa Extract GreenCare 79,14 mg/mL

    Time frame: Up to 5 days

Secondary outcomes

  1. Frequency, intensity, and severity of adverse events

    Time frame: Up to 5 days

  2. Plasma concentrations of CBD and THC

    Time frame: Up to 5 days

Study contacts

Contact information is provided by the study sponsor or research team.

Fabio Furtado

CONTACT

[email protected]

+5511942562895

Helena Joaquim, MsC, PhD

CONTACT

[email protected]

+5511942562895

Sponsors and collaborators

Lead sponsor

GreenCare Pharma

Industry

Registry information

Official study title

Phase I Clinical Trial to Assess Tolerability, Safety, and Pharmacokinetics of Extrato de Cannabis Sativa GreenCare 79.14 mg/mL - Drops Solution - in Healthy Research Participants of Both Sexes in a Fed State

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Feb 4, 2025
Registry last updated
Mar 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.